M
GLUE
Monte Rosa Therapeutics, Inc.
10.84
-0.27-2.43%After Hours: 10.84 0.00 0.00%19:30 10/23 EDT
OPEN/PREV CLOSE11.03/11.11
TODAY RANGE10.61-11.03
VOL817.83K
MARKET CAP924.80M
52 WEEK RANGE8.94-25.77
AVG VOL (3M)1.40M
% TURNOVER0.77%
TURNOVER--
P/E (TTM)-6.2259
% RANGE3.60%
EPS(TTM)-1.7411
P/E(FORWARD)-7.4117
P/B1.896
BVPS5.72
DIVIDEND--
P/S5.74
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP907.79M
SHARES OUTSTANDING85.31M
NEXT EARNINGS11/04-11/09
FREE FLOAT83.74M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Dow Jones·10/12 13:47
Monte Rosa Therapeutics Price Target Raised to $19.00/Share From $17.00 by UBS
Dow Jones·10/12 13:47
Monte Rosa Therapeutics Coverage Assumed by UBS at Buy
TipRanks·10/11 23:45
Monte Rosa Therapeutics assumed with a Buy at UBS
Simply Wall St·10/05 10:13
Monte Rosa Therapeutics (GLUE) Following Phase 1 Data Faces A Big Fair Value Question
Simply Wall St·10/03 06:24
Monte Rosa Therapeutics Stock In Focus After Phase 1 Data Win
TipRanks·10/02 12:55
Wedbush Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)
TipRanks·10/02 11:15
Guggenheim Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE)
TipRanks·10/02 11:15
Piper Sandler Remains a Buy on Monte Rosa Therapeutics (GLUE)
NASDAQ·10/01 16:59
Monte Rosa's MRT-8102 Drives 80%-90% NEK7 Degradation In Phase 1
Benzinga·10/01 16:44
Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular Disease
NASDAQ·10/01 16:36
MRT-8102 Delivers Broad Inflammation Reductions In Monte Rosa Trial
Same Industry
Name/Symbol
Change%
Price